|Bid||28.25 x 200|
|Ask||32.00 x 400|
|Day's Range||31.71 - 33.24|
|52 Week Range||24.45 - 55.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 21, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.91|
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Workday, ...
The Medicines Company will host a conference call and webcast on Wednesday, February 21, 2018, at 8:30 a.m., Eastern Time, to discuss fourth-quarter and full-year 2017 financial results and operational developments.
The Medicines Company today announced that it will participate in the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018, in New York City.
The end of the third sentence of the first paragraph of the release should read: then followed to the end of the study at 540 days ).
Esperion Therapeutics Inc (NASDAQ: ESPR ) is finishing research on its bemepedoic acid for lipid management, and while the Street expects success, the drug’s potential is weighted by a dearth of interested ...
Investors in Medicines Company (MDCO) need to pay close attention to the stock based on moves in the options market lately.
Stock Monitor: Melinta Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 10, 2018 / Active-Investors.com has just released a free research report on The Medicines Co. (NASDAQ: MDCO ...
Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to Baxter.
—Expands portfolio to four marketed antibiotics, with peak sales potential over $1 billion—— Creates premier commercial stage global antibiotic franchise with the addition of Vabomere™, Orbactiv ®, and ...
The Medicines Company today announced the closing of the sale of its infectious disease business unit to Melinta Therapeutics, Inc. for consideration consisting of $215 million of guaranteed cash, approximately 3.3 million shares of Melinta common stock, tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbactiv® and Minocin® IV, and the assumption by Melinta of all royalty, ...
We take a look at four companies with a favorable Zacks Rank that performed well in 2017 and are likely to continue on the growth path in 2018 as well.
The Medicines Company today announced that its Chief Executive Officer, Clive Meanwell, M.D., Ph.D., will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018, at 8:30 a.m., Pacific Time, at The Westin St.